Acrivon Therapeutics gets FDA breakthrough device designation for its oncosignature assay for endometrial cancer [Seeking Alpha]
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is now covered by analysts at KeyCorp. They set an "overweight" rating on the stock.